Search | Clinical Trials Finder

Conditions: Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
Interventions: Pitolisant; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 71
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Diabetic Macular Edema
Interventions: RO7446603, Aflibercept, Faricimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 70
States / cities: Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more

Conditions: Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis, Thrombus; Embolism, Embolism, Cardiovascular Diseases, Vascular Diseases
Interventions: Symphony Thrombectomy System; Device
Lead sponsor: Imperative Care, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Huntsville, Alabama • Los Angeles, California • Jacksonville, Florida + 15 more

Conditions: Depression
Interventions: N-acetyl cysteine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 15 Years to 24 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Mitral Regurgitation, Mitral Valve Regurgitation
Interventions: MitraClip® NT System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Mountain View, California + 25 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: V3381, Placebo; Drug
Lead sponsor: Vernalis (R&D) Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • Ocala, Florida • St. Petersburg, Florida + 5 more

Conditions: Colorectal Cancer
Interventions: Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil; Biological · Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 56
States / cities: Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more

Conditions: Kidney Transplant Rejection
Interventions: AT-1501, Tacrolimus; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 26
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 22 more

Conditions: Chronic Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 55 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 72
States / cities: Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: torcetrapib/atorvastatin, ezetimibe/simvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 123
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 1,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 27
States / cities: Los Angeles, California • Torrance, California • Denver, Colorado + 16 more

Conditions: HIV Infections
Interventions: atazanavir/ritonavir +2 NRTIs (immediate Switch Group), LPV/r +2 NRTIs (Delayed/optional Switch Group); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 12
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 9 more

Conditions: Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 106
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more

Conditions: Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Interventions: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 16
States / cities: Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more

Conditions: Healthy
Interventions: RTA 408 Lotion 0.5%, 1%, 3%, Lotion vehicle/placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Tuberous Sclerosis Complex
Interventions: Early Vigabatrin, Delayed Vigabatrin (Placebo); Drug
Lead sponsor: Martina Bebin; Other
Eligibility: 1 Day to 6 Months
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Essential Tremor
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 26
States / cities: Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more

Conditions: Systolic Heart Failure
Interventions: Probenecid 1 gr oral twice daily, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hyperlipidemia
Interventions: Evolocumab, Placebo to Evolocumab; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 55
States / cities: Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more

Conditions: Biliary Atresia
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 6 Months
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Neoplasms, Prostate
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 8,231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 297
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more

Conditions: Low-Dose Liver Radiation (LD-LRT), Non Small Cell Lung Cancer, Melanoma, Liver Metastases
Interventions: LD-LRT; Radiation
Lead sponsor: Jordan Kharofa; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

SYMPHONY-PE Study for Treatment of Pulmonary Embolism

N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR

Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

RTA 408 Lotion in Healthy Volunteers

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

A Prospective Database of Infants With Cholestasis

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

Promoting Immunotherapy Efficacy With Low-Dose Liver RT